NPM1和IDH1/2突变在复发/耐药AML中显示有限的预后影响:来自AVALON队列的证据
Calogero Vetro1, Irene Azzali2, Elisabetta Petracci2
1Hematology and Bone Marrow Transplantation Unit, Hospital of Bolzano (SABES-Azienda Sanitaria dell'Alto Adige), Teaching Hospital of Paracelsus Medical University, Bolzano, Italy.
Hematological oncology
|January 13, 2026
概括
在用venetoclax和低甲基化剂治疗的复发性/耐药性急性髓性白血病 (AML) 中,NPM1和IDH1/2等常见突变没有影响结果. 在预测AML预后方面,治疗背景比基线突变更重要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 复发性/耐药性急性髓性白血病 (AML) 的预后不佳.
- 威尼托克拉克斯加上低甲基化剂是AML的标准治疗方法.
- 识别预测性生物标志物对于优化AML治疗至关重要.
研究的目的:
- 评估NPM1和IDH1/2突变在复发/耐药AML患者的预后影响,这些患者接受了venetoclax加上低甲基化剂的治疗.
- 为了确定基线突变状态是否会影响AML小组中的治疗反应和生存率.
主要方法:
- 对AVALON队列数据的分析.
- 复发/耐药AML患者的回顾性研究.
- 评估NPM1和IDH1/2突变状态和与临床结果的相关性.
主要成果:
- NPM1突变没有显著影响反应或生存.
- IDH1/2突变对反应或生存没有显著影响.
- 用venetoclax加上低甲基化剂的治疗产生了类似的结果,无论这些突变如何.
结论:
- NPM1和IDH1/2突变不是治疗venetoclax和低甲基化剂的复发性/耐药性AML的显著预后因素.
- 复发性AML的预后模型应该优先考虑治疗背景,而不是基线突变状态.
- 进一步的研究可能会确定与这种治疗环境相关的其他生物标志物.
相关概念视频
03:18Non-LTR Retrotransposons
13.1K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.1K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K